Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
出版年份 2023 全文链接
标题
Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
作者
关键词
-
出版物
ADVANCES IN THERAPY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-01-11
DOI
10.1007/s12325-022-02423-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
- (2022) Domenica M. Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
- (2022) John P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
- (2022) W. Timothy Garvey et al. NATURE MEDICINE
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions
- (2020) Sandra Lopes et al. PHARMACOECONOMICS
- Obesity Prevalence in the Long-Term Future in 18 European Countries and in the USA
- (2020) Fanny Janssen et al. Obesity Facts
- Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation
- (2017) G.A. Bray et al. Obesity Reviews
- Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study
- (2017) Julia Hippisley-Cox et al. BMJ-British Medical Journal
- Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
- (2017) Julia Hippisley-Cox et al. BMJ-British Medical Journal
- Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study
- (2017) Julia Hippisley-Cox et al. BMJ-British Medical Journal
- Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study
- (2017) Julia Hippisley-Cox et al. BMJ-British Medical Journal
- What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
- (2014) R Ara et al. HEALTH TECHNOLOGY ASSESSMENT
- UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82
- (2013) A. J. Hayes et al. DIABETOLOGIA
- The association of body mass index and health-related quality of life in the general population: data from the 2003 Health Survey of England
- (2009) F. Søltoft et al. QUALITY OF LIFE RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now